Cargando…
Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells
SIMPLE SUMMARY: The incidence rate of metastatic melanoma has been rapidly increasing worldwide and its 5-year survival rate is very low. Due to partial responses, various side effects, and resistance to any known cancer therapeutics, more potent and safer therapeutics are needed to increase the sur...
Autores principales: | Lee, Min Seung, Lim, So Hyun, Yu, Ah-Ran, Hwang, Chi Yeon, Kang, Insug, Yeo, Eui-Ju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918982/ https://www.ncbi.nlm.nih.gov/pubmed/33671902 http://dx.doi.org/10.3390/biology10020153 |
Ejemplares similares
-
Carfilzomib enhances cisplatin-induced apoptosis in SK-N-BE(2)-M17 human neuroblastoma cells
por: Lee, Song-I, et al.
Publicado: (2019) -
Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013) -
Compound C Inhibits B16-F1 Tumor Growth in a Syngeneic Mouse Model via the Blockage of Cell Cycle Progression and Angiogenesis
por: Lee, Yun Taek, et al.
Publicado: (2019) -
Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines
por: Takahashi, Kazuya, et al.
Publicado: (2017) -
Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib
por: Karademir, Betul, et al.
Publicado: (2018)